Outlook Therapeutics, INC Schedule 13D activist filings
Filed when an investor crosses five percent and intends to influence the company — the activist disclosure.
NASDAQ
GMS Ventures and Investments, along with Ghiath M. Sukhtian, have updated their Schedule 13D filing to reflect their beneficial ownership in Outlook Therapeutics, Inc. following a recent public offering.
NASDAQ
GMS Ventures and Investments has invested $5 million in Outlook Therapeutics through a registered direct offering, increasing its beneficial ownership to 22.9%.
NASDAQ
SCHEDULE 13D/A: GMS Ventures Increases Stake in Outlook Therapeutics to Over 50% Following $6 Million Public Offering Investment
GMS Ventures and Ghiath M. Sukhtian have significantly increased their beneficial ownership in Outlook Therapeutics, Inc. to 50.3% after investing $6 million in the company's May 2025 Public Offering.
NASDAQ
SCHEDULE 13D/A: Major Shareholder Updates Outlook Therapeutics Stake to 41.6% Following Corporate Charter Amendment
GMS Ventures and Ghiath M. Sukhtian have updated their beneficial ownership in Outlook Therapeutics, Inc. to 41.6% following an amendment to the Issuer's Restated Certificate of Incorporation.
NASDAQ
SCHEDULE 13D/A: GMS Ventures Increases Stake in Outlook Therapeutics to 38.6% Through Warrant Exercise and Inducement Offer
GMS Ventures and Ghiath M. Sukhtian have updated their beneficial ownership in Outlook Therapeutics, Inc. to 38.6% following the exercise of existing warrants and the receipt of new inducement warrants.